论文部分内容阅读
目的:高迁移率族蛋白1(high mobility group box-1 protein,HMGB1)是一个多功能细胞因子,与细胞移动和肿瘤浸润有关。本研究通过检测胃癌病人血清HMGB1水平,分析其与胃癌临床病理特征的关系,并与肿瘤标志物CA19-9、CEA进行比较,探讨胃癌病人血清中HMGB1的含量及其临床意义。方法:分别采用ELISA法和化学发光免疫法检测160例胃癌病人术前血清HMGB1、CA19-9和CEA含量和52例胃良性疾病病人、60例正常对照者的血清HMGB1含量,123例胃癌病人同时检测根治术后血清HMGB1含量。结果:胃癌病人血清HMGB1水平(13.1±7.6)ng/mL明显高于正常对照组(4.5±2.9)ng/mL(Р<0.001)和胃良性疾病组(5.2±3.4)ng/mL(Р<0.001)。分层分析发现,随着疾病的进展,血清HMGB1水平逐渐升高,TNMⅢ期和Ⅳ期分别与Ⅰ期进行比较,均有显著差异(Р<0.001)。肿瘤浸润浆膜(Р<0.001)、有淋巴结转移(Р<0.001)及肝脏转移者(Р=0.026)的血清HMGB1水平升高更为明显。根治术后血清HMGB1水平(8.5±5.2)ng/mL比术前(12.4±7.6)ng/mL明显降低(Р<0.001)。此外,160例病人血清HMGB1、CA19-9和CEA的阳性率分别为66.2%、14.3%和8.7%,HMGB1阳性率明显高于CA19-9(Р<0.001)和CEA(Р<0.001)。结论:胃癌病人血清HMGB1水平明显高于正常对照组和胃良性疾病组,且血清HMGB1的表达水平与胃癌的浆膜浸润、淋巴结转移及肝脏转移呈正相关,血清HMGB1表达水平可作为反映胃癌生物学行为和术后随访、监测的参考指标。
OBJECTIVE: High mobility group box-1 protein (HMGB1) is a multifunctional cytokine that is involved in cell migration and tumor invasion. In this study, the serum levels of HMGB1 in gastric cancer patients were determined, and their relationship with clinicopathological features of gastric cancer was analyzed. The levels of serum HMGB1 in gastric cancer patients and their clinical significance were compared with those of tumor markers CA19-9 and CEA. Methods: The serum levels of HMGB1, CA19-9 and CEA in 160 patients with gastric cancer and 52 patients with gastric benign disease and 60 normal controls were measured by ELISA and chemiluminescence immunoassay. The serum levels of HMGB1 in 123 gastric cancer patients Detect the content of serum HMGB1 after radical operation. Results: Serum levels of HMGB1 in gastric cancer patients were significantly higher than those in normal controls (13 ± 7.6) ng / mL (4.5 ± 2.9) ng / mL (5.2 ± 3.4) ng / mL 0.001). Hierarchical analysis showed that serum HMGB1 levels gradually increased as the disease progressed. TNM stages III and IV were significantly different from those in stage Ⅰ (P0.001). Serum-infiltrated serosal membrane (P0.001) showed a significant increase in serum HMGB1 levels with lymph node metastasis (P0.001) and liver metastasis (0.026). The serum HMGB1 level after radical operation (8.5 ± 5.2) ng / mL was significantly lower than that before operation (12.4 ± 7.6) ng / mL (P0.001). In addition, the positive rates of serum HMGB1, CA19-9 and CEA were 66.2%, 14.3% and 8.7% respectively in 160 patients. The positive rate of HMGB1 was significantly higher than that of CA19-9 (P0.001) and CEA (P0.001). Conclusion: The level of serum HMGB1 in patients with gastric cancer is significantly higher than that in normal controls and benign gastric diseases. The serum level of HMGB1 is positively correlated with serosal invasion, lymph node metastasis and liver metastasis. The serum level of HMGB1 can be used as a marker of gastric cancer biology Behavioral and postoperative follow-up, monitoring of reference indicators.